Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overexpression of phospho mutant forms of transglutaminase 2 downregulates epidermal growth factor receptor.

Biochemical and biophysical research communications - 6 Jan 2012

Wang Yi, Ande Sudharsana R, Mishra Suresh

Abstract excerpt

Simultaneous upregulation of transglutaminase 2 (TG2) and epidermal growth factor receptor (EGFR) have been reported in a number of systems. Moreover, TG2 has been identified as a downstream target gene for EGF/EGFR. However, it is not known whether the relationship between EGFR and TG2 is only one-way or collaborative. Using embryonic fibroblasts derived from TG2 null mice (MEF(tg2-/-)), co-overexpressing native...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Down-Regulation
Share to ErbB Receptors
Share to GTP-Binding Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Mutant Strains

Share to Phosphorylation

Share to Protein Glutamine gamma Glutamyltransferase 2

Share to Proto-Oncogene Proteins c-akt

Share to Transglutaminases

Source

Identifiers

PMID: 22142843
DOI: 10.1016/j.bbrc.2011.11.094

Genes

EGFR
EGF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overexpression of phospho mutant forms of transglutaminase 2 downregulates epidermal growth factor receptor.PMID 22142843Read ↗

The Role of Transglutaminase 2 in Cancer: An UpdateSemantic proximity Read ↗

Transglutaminase 2 takes center stage as a cancer cell survival factor and therapy targetSemantic proximity Read ↗

Tissue transglutaminase: a new target to reverse cancer drug resistanceSemantic proximity Read ↗

Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells.Semantic proximity Read ↗

Transglutaminase 2 enhances hepatocyte growth factor signaling to drive the mesothelioma cancer cell phenotype.Semantic proximity Read ↗

Transglutaminase 2 Maintains Hepatocyte Growth Factor Signaling to Enhance the Cancer Cell Phenotype.Semantic proximity Read ↗

Tpl-2 kinase downregulates the activity of p53 and enhances signaling pathways leading to activation of activator protein 1 induced by EGF.Semantic proximity Read ↗

Tissue-specific responses to loss of transglutaminase 2.Semantic proximity Read ↗

Tissue transglutaminase: from biological glue to cell survival cues.Semantic proximity Read ↗

Heterodimerization of c-erbB2 with different epidermal growth factor receptor mutants elicits stimulatory or inhibitory responses.Semantic proximity Read ↗

Role of tissue transglutaminase 2 in the acquisition of a mesenchymal-like phenotype in highly invasive A431 tumor cells.Semantic proximity Read ↗

Constitutive activity of JNK2 alpha2 is dependent on a unique mechanism of MAPK activation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.